The disposition of cefotaxime (CTX) and desacetyl cefotaxime (DAC) was studied in eight noninfected patients on continuous ambulatory peritoneal dialysis. Each patient received a single intravenous (i.v.) infusion and an intraperitoneal (i.p.) instillation of 2 g of CTX. Multiple blood and dialysate samples were collected during the 72-h period after drug administration. The half-life, steady-state volume of distribution, and total body clearance of CTX following i.v. administration were 2.2 ± 1.0 h (mean ± standard deviation), 0.17 ± 0.03 liters/kg, and 81.0 ± 31.0 ml/min, respectively. No significant differences were observed in these parameters after i.p. administration. The continuous ambulatory peritoneal dialysis clearances of CTX and DAC were 1.82 ± 0.43 and 2.84 ± 0.70 ml/min, respectively, after i.v. administration. The bioavailability of CTX after i.p. instillation was 74.6 ± 21.3%. Peak peritoneal dialysate CTX and DAC concentrations of 264.3 and 25.8 mg/liter, respectively, were observed after i
pg/mI).
Cefotaxime (CTX) is a cephalosporin with a broad spectrum of activity, including both gram-positive and gramnegative organisms (7) . Its primary metabolite, desacetyl cefotaxime (DAC), which is further metabolized to two inactive compounds, has been shown to be approximately one-fourth to one-eighth as active as CTX and more active than cefazolin, cefamandole, or cefoxitin against many bacteria (4, 9, 11) . Furthermore, synergy has been noted for up to 76% of organisms evaluated in the presence of CTX and DAC (8, 9, 11) . In light of these antimicrobial characteristics, CTX may be useful for the treatment of peritonitis and systemic infections in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Although the renal clearance of CTX in patients with end-stage renal disease is significantly decreased, the halflife is generally less than 3 h (6, 10, 13) . Thus, frequent doses may be required to maintain effective plasma and peritoneal fluid concentrations. This study was designed to characterize the plasma and peritoneal fluid concentration-time profile of CTX and DAC after intravenous (i.v.) and intraperitoneal (i.p.) administration of CTX, and to determine the bioavailability of CTX when administered i.p. The pharmacokinetic parameters of CTX and DAC were calculated, and dosage regimens for the treatment of peritonitis and systemic infections with CTX in CAPD patients are proposed.
MATERIALS AND METHODS
The study was approved by the Research Advisory Committee of Hennepin County Medical Center, Minneapolis, Minn. Eight anuric subjects with no known hypersensitivity to cephalosporins participated in the study after granting written informed consent. All subjects had been on CAPD for a minimum of 4 months, and none had peritonitis in the 3 months before the study. A medical history and physical * Corresponding author. examination, chest radiograph, electrocardiogram, and hematological and biochemical screening profile were completed for each subject before study participation. Subjects with unstable renal function or gastrointestinal or liver diseases were excluded. No subject had received an investigational drug or antimicrobial agent in the 4 weeks before the study. Each subject had an indwelling Tenckhoff catheter. The CAPD exchange schedule for each participant was 2 liters of 2.5% dextrose peritoneal dialysis solution (Dianeal; Travenol Laboratories, Inc., Deerfield, Ill.) every 6 h.
Each subject received an i.p. and an i.v. dose of CTX in a randomized fashion separated by at least 72 h. The single 2-g dose of CTX sodium (lot RP4018; Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.) was instilled i.p. after an overnight fast in the first exchange of the day (approximately 8 a.m.). Blood samples (10 ml) were collected from a forearm vein before instillation of the i.p. dose and 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 15, 18, 24, 30, 36, 48, 60, and 72 h after instillation. Dialysate fluid specimens (10 ml) were also collected at 0.25, 0.5, 1, 3, and 6 h after instillation. In addition, each subject received a single 2-g i.v. dose of CTX sodium (lot RP4018) diluted in 50 ml of 5% dextrose. The drug was infused into a forearm vein over a 5-min period. Blood samples were collected from a forearm vein in the contralateral arm before drug administration and 0.08, 0.16, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 18, 24, 36, 48, 60 , and 72 h after the start of the i.v. infusion. During each of the 72-h study periods, total dialysate outflow of each exchange was collected and measured, and a sample was retained. Plasma and dialysate samples were stored at -70°C until analysis.
The concentrations of CTX and DAC in plasma and dialysate were determined by a modification of the highperformance liquid chromatography technique of Chamberlain et al. (4) . The chromatographic system (Waters Associates, Inc., Milford, Mass.) consisted of a U6K injection port, (12) . These parameters could not be calculated for DAC since the dose was unknown.
The bioavailability (F) of i.p. instilled CTX was calculated as: F = (AUCi.p./AUCi.v.) (dosei.,./dosei.p.) (2) where dosei.p. is the amount administered minus the amount recovered in the first dialysate effluent. The CAPD clearance of CTX, DAC, and creatinine following i.v. and i.p. administration was calculated as: CLCAPD = Adtl_t2/AUCtlt,2 (3) where Ad,1_,2 is the amount of compound recovered in the dialysate, and AUC,1,2 is the area under the plasma concentration-time curve during the same time interval.
A paired Student's t test was used to compare the pharmacokinetic parameters of CTX and DAC after i.v. and i.p. CTX administration. Statistical significance for all tests I I ' I I (1) where C, is the concentration in plasma at time t, A and B are the intercepts, and a and a are the disposition rate constants obtained from the first and second phases, respectively, of the plot of log CTX concentration in plasma versus time. was assessed at the P < 0.05 level. Results are expressed as mean ± standard deviation.
RESULTS
The demographic and clinical characteristics of the eight subjects who completed the protocol are listed in Table 1 . The CTX plasma concentration-time data after i.v. administration were biexponential in all patients (Fig. 1) . The peak plasma CTX concentration after i.p. administration was 29.7 ± 9.2 mg/liter and was less than 10% of that achieved after i.v. administration (322.9 mg/liter). Peak plasma concentrations of DAC after i.p. administration (19.5 mg/liter) were observed later (7.1 versus 4.8 h) and approximated 50% of the concentration observed after i.v. administration (37.8 mg/liter).
The maximum peritoneal dialysate concentrations of CTX and DAC of 17.7 ± 4.8 and 11.4 ± 7.4 mg/liter, respectively, were observed 6 h after i.v. administration of CTX and declined at a rate similar to the plasma t1/2 of each compound (Fig. 2) . The peritoneal dialysate concentrations of CTX and DAC (264.3 ± 137.1 and 25.8 ± 6.4 mg/liter, respectively) after the 6-h i.p. instillation period were significantly greater than those observed 6 h after i.v. administration (Fig. 2) The CLCAPD of CTX after both routes of administration was significantly less than its CLp (Table 2 ). The CLCAPD of CTX after i.p. doses, however, was significantly greater than that observed after i.v. doses (11.5 ± 6.9 versus 1.8 ± 0.4 ml/min). Unlike CTX, no significant difference was observed in CLCAPD of DAC after i.v. and i.p. CTX administration (2.8 0.7 and 3.5 ± 1.0 m/min, respectively). Likewise, the CLCAPD of creatinine did not significantly differ from i.v. and i.p. doses (4.5 ± 0.4 and 4.5 0.7 ml/min, respectively).
DISCUSSION
The CLp, Vss, and t1/2 of CTX after i.v. administration to CAPD patients are not significantly different from previously reported values of 107.6 ml/min, 0.25 liter/kg, and 2.5 h in nondialyzing end-stage renal disease patients (10) . The mean t1/2 of DAC of 18.9 h in these eight patients is longer but not significantly different from previous reports (10) . No clinically significant alteration in CTX or DAC disposition after i.v. administration was apparent in these CAPD patients. These findings are comparable to a recent assessment of CTX and DAC disposition after i.v. CTX administration to CAPD patients (1) . Although the CTX t1,2 was almost identical (2.2 versus 2.7 h), the DAC t1/2 reported by this group was approximately 7 h less than the value observed in the present study. This may be due, in part, to the shorter time period over which plasma concentrations were monitored (12 versus 
